Design of future acute-stroke treatment trials (Q35172350)

6 August 2017

1 reference

title

Design of future acute-stroke treatment trials (English)

1 reference

6 August 2017

Graeme J Hankey

2

0 references

author name string

Kennedy R Lees

series ordinal

1

1 reference

6 August 2017

Werner Hacke

series ordinal

3

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

2

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

54-61

1 reference

Trends in acute ischemic stroke trials through the 20th century

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Tissue plasminogen activator for acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Thrombolytic therapy with streptokinase in acute ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Infarcts of undetermined cause: the NINCDS Stroke Data Bank

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Infarcts with a cardiac source of embolism in the NINCDS Stroke Data Bank: historical features

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Classification and natural history of clinically identifiable subtypes of cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Validation of a clinical classification for subtypes of acute cerebral infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Combination Therapy Stroke Trial: recombinant tissue-type plasminogen activator with/without lubeluzole

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Cerebral vascular accidents in patients over the age of 60. II. Prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Trials of thrombolysis in acute ischemic stroke: does the choice of primary outcome measure really matter?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

1 reference

7 January 2021

Bootstrap statistics of ECASS II data: just another post hoc analysis of a negative stroke trial?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

Recommendations for clinical trial evaluation of acute stroke therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2803%2900267-9

7 January 2021

10.1016/S1474-4422(03)00267-9

Identifiers

DOI

1 reference

6 August 2017

1 reference